Mmadụ EML4-ALK Fusion Gene Mutation

Nkọwa dị mkpirikpi:

A na-eji ngwa a chọpụta nke ọma ụdị mmụgharị iri na abụọ nke EML4-ALK fusion gene n'ihe atụ nke ndị ọrịa kansa akpa ume mmadụ na-adịghị ahụkebe na vitro.Nsonaazụ ule a bụ maka ntụaka ụlọọgwụ naanị na ekwesighi iji ya dịka naanị ihe ndabere maka ọgwụgwọ n'otu n'otu nke ndị ọrịa.Ndị dọkịta kwesịrị ime mkpebi zuru oke na nsonaazụ ule dabere na ihe ndị dị ka ọnọdụ onye ọrịa, ihe ngosi ọgwụ, nzaghachi ọgwụgwọ, na ihe ngosi nyocha ụlọ nyocha ndị ọzọ.


Nkọwa ngwaahịa

Mkpado ngwaahịa

Aha ngwaahịa

HWTS-TM006-Human EML4-ALK Fusion Gene Mutation Detection Kit(Fluorescence PCR)

Asambodo

CE

Epidemiology

A na-eji ngwa a chọpụta nke ọma ụdị mmụgharị iri na abụọ nke EML4-ALK fusion gene na ihe atụ nke ndị ọrịa cancer akpa ume mmadụ na-abụghị obere cell na vitro.Nsonaazụ ule a bụ maka ntụaka ụlọọgwụ naanị na ekwesighi iji ya dịka naanị ihe ndabere maka ọgwụgwọ n'otu n'otu nke ndị ọrịa.Ndị dọkịta kwesịrị ime mkpebi zuru oke na nsonaazụ ule dabere na ihe ndị dị ka ọnọdụ onye ọrịa, ihe ngosi ọgwụ, nzaghachi ọgwụgwọ, na ihe ngosi nyocha ụlọ nyocha ndị ọzọ.Ọrịa cancer akpa ume bụ ọrịa na-adịghị mma n'ụwa niile, na 80% ~ 85% nke ikpe ahụ bụ ọrịa cancer akpa ume na-abụghị obere cell (NSCLC).Gene fusion nke echinoderm microtubule-sociated protein-dị ka 4 (EML4) na anaplastic lymphoma kinase (ALK) bụ ihe ọhụrụ lekwasịrị anya na NSCLC, EML4 na ALK dị n'otu n'otu dị n'ime mmadụ P21 na P23 bands na chromosome 2 ma kewapụrụ site na ihe dịka 12.7 nde isi ụzọ abụọ.Opekempe, achọtala ụdị fusion 20, n'ime nke 12 fusion mutants dị na Tebụl 1 na-ahụkarị, ebe mutant 1 (E13; A20) bụ nke a na-ahụkarị, na-esote mutant 3a na 3b (E6; A20), na-aza ajụjụ maka ihe dịka. 33% na 29% nke ndị ọrịa nwere EML4-ALK fusion gene NSCLC, n'otu n'otu.Ndị na-egbochi ALK nke Crizotinib nọchitere anya ya bụ obere ọgwụ ezubere iche maka mmụkọ mkpụrụ ndụ ALK.Site n'igbochi ọrụ nke mpaghara ALK tyrosine kinase, na-egbochi ụzọ mgbaàmà ya na-adịghị mma, si otú ahụ na-egbochi uto nke mkpụrụ ndụ tumo, iji nweta ọgwụgwọ ezubere iche maka etuto ahụ.Nnyocha ụlọ ọgwụ egosila na Crizotinib nwere ọnụọgụ dị irè karịa 61% na ndị ọrịa nwere mgbanwe mgbanwe EML4-ALK, ebe ọ fọrọ nke nta ka ọ ghara inwe mmetụta na ndị ọrịa anụ ọhịa.Ya mere, nchọpụta nke EML4-ALK fusion mutation bụ ntọala na ndabere maka nduzi iji ọgwụ Crizotinib.

Ọwa

FAM Ihe nchekwa mmeghachi omume 1, 2
VIC(HEX) Ihe nchekwa mmeghachi omume 2

Nka nka

Nchekwa

≤-18℃

Ndụ nchekwa

Ọnwa 9

Ụdị ụdị

paraffin-agbakwunyere anụ ahụ pathological ma ọ bụ ihe nlele ngalaba

CV

5.0%

Ct

≤38

LoD

Ngwa a nwere ike ịchọpụta mmụgharị nke njikọ dị obere ka nnomi 20.

Ngwa ngwa:

Ngwa Biosystem 7500 ezigbo oge PCR Sistemu

Ngwa Biosystem 7500 Ngwa PCR ngwa ngwa ozugbo

Sistemụ PCR SLAN ®-96P ezigbo oge

QuantStudio™ 5 Sistemụ PCR ezigbo oge

Sistemụ PCR Real-Time LightCycler®480

Sistemụ nchọpụta PCR nke LineGene 9600 Plus

MA-6000 Real-Time Quantitative Thermal Cycler

BioRad CFX96 ezigbo oge PCR sistemụ

BioRad CFX Opus 96 PCR ezigbo oge

Usoro ọrụ

Reagent mmịpụta akwadoro: Ngwa RNeasy FFPE (73504) nke QIAGEN, Ngalaba Tissue agbakwunyere Paraffin Mkpokọta ngwa mmịpụta RNA (DP439) nke Tiangen Biotech(Beijing) Co., Ltd.


  • Nke gara aga:
  • Osote:

  • Dee ozi gị ebe a ziga anyị ya